Green Cross Cell Receives Approval for Phase 3 Clinical Trial Plan of ImmunCell-LC Injection Combined with Gemcitabine Therapy
[Asia Economy Reporter Oh Ju-yeon] Green Cross Cell announced on the 21st that it has received approval from the Ministry of Food and Drug Safety for a Phase 3 clinical trial plan comparing ImmunCell-LC injection combined with gemcitabine versus gemcitabine monotherapy as adjuvant therapy after resection surgery in patients with pancreatic ductal adenocarcinoma.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
